Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150534 · ClinicalTrials.gov registry record
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 22
- Enrollment target
NCT06150534: Completed study, sponsored by Takeda.
NCT06150534 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06150534 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The main aim of this study is to determine the impact of digital health technology, such as Alexa Skill, used to support the initiation of home-based subcutaneous immunoglobulin (SCIG) treatment, treatment management, and overall participant experience.
Primary Outcome
Qualitative interviews with patients, caregivers, and HCPs who will be using the Alexa Skill to support initiation of SCIG for PID to characterize their experience, including convenience and satisfaction. Qualitative interviews will be semi-structured to comprehensively assess confidence and satisfaction, but also open-ended to give patients, families, and HCPs freedom to discuss their experience.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2025-02-28 |
What the finished NCT06150534 record still lists
NCT06150534 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT06150534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06150534 about?
NCT06150534 is a clinical study titled "At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill". The main aim of this study is to determine the impact of digital health technology, such as Alexa Skill, used to support the initiation of home-based subcutaneous immunoglobulin (SCIG) treatment, treatment management, and overall participant experience.
What is the current status of trial NCT06150534?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2023-12-27. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT06150534?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06150534?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI